Susanne Krege1. 1. Klinik für Urologie, Kinderurologie und urologische Onkologie, Kliniken Essen Mitte, Hyussens-Stiftung, Henricistraße 92, 45136, Essen, Deutschland. s.krege@kliniken-essen-mitte.de.
Abstract
BACKGROUND: Testicular cancer is a disease of young adult men, and it is curable in most cases. Even in advanced disease, cure rates reach 80 % nowadays. This was achieved by consistently performing studies concerning the different stages of disease. TREATMENT AND FOLLOW-UP CARE: The concept of treatment is interdisciplinary. After removal of the affected testis, histology and stage determine further therapy, which can be active surveillance, polychemotherapy, radiotherapy, surgery, or a combination of these. Curability also has consequences for the long-term follow-up. We speak about long-term survivorship. Besides looking for recurrences, it is also necessary to observe and treat long-term toxicities caused by the different therapeutic procedures. CONCLUSION: Because testicular cancer is rare with about 4500 cases annually, treatment-especially for advanced disease-should be performed at centers. In addition, it is possible to obtain a second opinion using the Interdisciplinary German Testicular Study Group website.
BACKGROUND:Testicular cancer is a disease of young adult men, and it is curable in most cases. Even in advanced disease, cure rates reach 80 % nowadays. This was achieved by consistently performing studies concerning the different stages of disease. TREATMENT AND FOLLOW-UP CARE: The concept of treatment is interdisciplinary. After removal of the affected testis, histology and stage determine further therapy, which can be active surveillance, polychemotherapy, radiotherapy, surgery, or a combination of these. Curability also has consequences for the long-term follow-up. We speak about long-term survivorship. Besides looking for recurrences, it is also necessary to observe and treat long-term toxicities caused by the different therapeutic procedures. CONCLUSION: Because testicular cancer is rare with about 4500 cases annually, treatment-especially for advanced disease-should be performed at centers. In addition, it is possible to obtain a second opinion using the Interdisciplinary German Testicular Study Group website.
Entities:
Keywords:
Long term adverse effects; Polychemotherapy; Prevention and control; Radiotherapy; Residual tumor resection
Authors: R Timothy D Oliver; Graham M Mead; Gordon J S Rustin; Johnathan K Joffe; Nina Aass; Robert Coleman; Rhian Gabe; Philip Pollock; Sally P Stenning Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Klaus-Peter Dieckmann; Arlo Radtke; Meike Spiekermann; Thomas Balks; Cord Matthies; Pascal Becker; Christian Ruf; Christoph Oing; Karin Oechsle; Carsten Bokemeyer; Johannes Hammel; Sebastian Melchior; Werner Wosniok; Gazanfer Belge Journal: Eur Urol Date: 2016-08-02 Impact factor: 20.096
Authors: T Tandstad; O Ståhl; U Håkansson; O Dahl; H S Haugnes; O H Klepp; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; E Cavallin-Ståhl; U Stierner; R Wahlquist; N Wall; G Cohn-Cedermark Journal: Ann Oncol Date: 2014-08-11 Impact factor: 32.976
Authors: Christian Kollmannsberger; Torgrim Tandstad; Philippe L Bedard; Gabriella Cohn-Cedermark; Peter W Chung; Michael A Jewett; Tom Powles; Padraig R Warde; Siamak Daneshmand; Andrew Protheroe; Scott Tyldesley; Peter C Black; Kim Chi; Alan I So; Malcom J Moore; Craig R Nichols Journal: J Clin Oncol Date: 2014-08-18 Impact factor: 44.544
Authors: P Warde; M K Gospodarowicz; D Banerjee; T Panzarella; L Sugar; C N Catton; J F Sturgeon; M Moore; M A Jewett Journal: J Urol Date: 1997-05 Impact factor: 7.450
Authors: A Horwich; S D Fossa; R Huddart; D P Dearnaley; S Stenning; M Aresu; J M Bliss; E Hall Journal: Br J Cancer Date: 2013-11-21 Impact factor: 7.640